CN1723988A - The pharmaceutical composition of kakkalide and application thereof - Google Patents
The pharmaceutical composition of kakkalide and application thereof Download PDFInfo
- Publication number
- CN1723988A CN1723988A CN 200510043968 CN200510043968A CN1723988A CN 1723988 A CN1723988 A CN 1723988A CN 200510043968 CN200510043968 CN 200510043968 CN 200510043968 A CN200510043968 A CN 200510043968A CN 1723988 A CN1723988 A CN 1723988A
- Authority
- CN
- China
- Prior art keywords
- kakkalide
- pharmaceutical composition
- group
- injection
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of kakkalide that extracts from Flos puerariae lobatae can be used for preparing the pharmaceutical composition for the treatment of the heart, cerebrovascular, contains kakkalide in this pharmaceutical composition, and pharmaceutically acceptable carrier.Kakkalide also can be used in preparation treatment osteoporosis agents.In the pharmaceutical composition of kakkalide, add the 0-50% solubilizing agent, can obviously improve the water solublity of kakkalide as hydroxy propyl-Beta-ring paste, beta-schardinger dextrin-, hydroxyethyl-etc., thereby improve its bioavailability.The kakkalide pharmaceutical composition that contains solubilizing agent can directly be made the injection that is used for the treatment of the heart, cerebrovascular and osteoporosis.
Description
Technical field
The present invention relates to the field of Chinese medicines, is about the application of plant extract kakkalide in the preparation new drug.
Background technology
Flos puerariae lobatae (Flos Puerariae) has another name called the Radix puerariae flower, is the dry flower of pulse family (Leguminosae) plant Herba Gelsemii Elegantis (Pueraria Lobata (Willd.) Ohwi).Cool in nature, sweet in the mouth goes into to return Yangming Channel.It has the effect of relieving acute alcoholism and recuperating the spleen record such as Shennong's Herbal, Compendium of Material Medica, cures mainly the diseases such as heating excessive thirst, anorexia, vomiting acid regurgitation, haematemesis, discharging fresh blood stool of getting sick from drinking too much wine.
Bibliographical information; Flos puerariae lobatae extract can significantly raise Gu/ZnSOD and CAI (catalase) activity in the rat model body of Ethanol Treatment; reduce G-SH-PX (glutathion peroxidase) activity; make the NRNA level and the liver GSH of these antioxidases recover normal; reduce the MAD level; liver is protected, and Flos puerariae lobatae also has gastric mucosal protective effect and digestive tube activation.
Chemical constituent of Flos puerariae lobatae and pharmacological action thereof are domestic not to appear in the newspapers as yet; foreign study reports that its chemical constituent is mainly osajin and saponins compound; kakkalide (kakkalide wherein; 5; 7-dihydroxy-6; 4 '-dimethoxyisoflavone-7-O-β-D-xylopyranosyl-6-O-β-D-glucopyranoside) is one of main active in the Flos puerariae lobatae; bibliographical information shows; kakkalide can effectively reduce the activity of AST and ALT in the serum; the integrity of protection liver plasma membrane; Yamazaki T report, 200mg/kg kakkalide also significantly suppress the increase of alcohol induced mouse blood sugar level, prevent the glycometabolic destruction that ethanol causes.Kakkalide is poisoned to alleviation of alcohol and the protection hepatic injury has curative effect preferably.
Flos puerariae lobatae is widely distributed in China, and plant resources is abundant, and wherein effective ingredient such as flavone, saponin has very strong pharmacologically active, has obtained extensive studies abroad.But domestic deep not enough to its chemical constituent, pharmacological action and Study of Clinical Application, mainly contain Flos puerariae lobatae in China at present and separate the soup of waking up and be used for clinically, health product such as Pueravia flower tea, Flos puerariae lobatae dews go on the market.Mainly be confined to relieve the effect of alcohol, hepatoprotective etc.And the other drug activity of Flos puerariae lobatae Chinese medicine active component kakkalide does not have deep research, and especially the purposes in medicines such as treatment ischemic cardio cerebrovascular diseases and osteoporosis is not seen bibliographical information.This Chinese medicine of Flos puerariae lobatae is still waiting further research, and medicinal application field and novel form and health product in the hope of exploitation makes new advances make it open up more wide purposes at aspects such as medical treatment, health cares.
Kakkalide can only be made the oral medicine preparation at present and can not make injection drug because water solublity hangs down when medicinal, because their water solublity is low, has influence on drug utilization degree and remarkable time, is not easy to select clinically use.
Summary of the invention
The object of the present invention is to provide the new purposes of a kind of kakkalide in the preparation treatment heart, cerebrovascular new drug.
It is fast that another object of the present invention provides good water solubility, bioavailability height, produce effects, but the kakkalide new drug preparation of the injection medicine treatment heart, cerebrovascular.
Of the present invention have a purpose to provide the application of kakkalide in preparation treatment osteoporosis medicine again.
Solution of the present invention is the kakkalide that extracts by in the plant effective sites such as Chinese medicine Flos puerariae lobatae, and its structural formula is:
R wherein
1Be Glc
6-Xyl R
2R
3Be OCH
3
Common name: kakkalide.
The chinesization formal name used at school: 5,7-dihydroxy-6,4 '-dimethoxy isoflavone-7-O-β-D-xylopyranose-6-O-β-D-pyranglucoside.
English name: kakkalide
English chemical name: 5,7-dihydroxy-6,4 '-dimethoxyisoflavone-7-O-β-D-xylopyranosyl-6-O-β-D-glucopyranoside.
The kakkalide main physical and chemical: kakkalide is colourless needle, molecular formula: C
28H
32O
15Molecular weight 608, mp.238～239 ℃, FeCl
3Reaction is positive, and the reaction of HCl-Mg powder is negative.IR(KBr)cm
-1：3500(OH)，3200，1651(C＝O)，1605，1580，1510。
13CNMR(DMSO-d
6，150MHz)：180.9，159.4，156.7，155.1，153.0，152.7，132.7，130.3，123.0，121.9，113.9，106.7，104.3，100.3，94.4，76.8，76.7，76.0，73.6，73.2，69.9，69.6，68.6，65.8，60.5，55.3。
1HNMR data (DMSO-d
6, 600MHz):
No. III
2 8.43(s)
5-OH 12.89(s)
6 /
7-OH /
8 6.97(s)
2′，6′ 7.52(d，8.5)
3′，5′ 7.01(d，8.5)
Glc-1 5.05(d，7.4)
2 3.35(m)
3 3.33(m)
4 3.21(m)
5 3.62(m)
6-a 3.64(m)
6-b 3.93(m)
Xyl-1 4.18(d，7.5)
2 3.00(m)
3 3.07(m)
4 3.31(m)
5-a 2.96(m)
5-b 3.70(m)
6-OMe 3.79(s)
4′-OMe 3.77(s)
4′-OH /
The applicant has carried out the anxious poison and the test of pesticide effectiveness with effective ingredient kakkalide of the present invention, has inquired into the mechanism of action of kakkalide at the treatment ischemic heart, cerebrovascular disease.And inquired into the effect of kakkalide to the treatment osteoporosis with rat.
One, kakkalide resisting oxygen lack
50 of Kunming mouses, male and female half and half are divided into 4 groups at random, and promptly blank group, kakkalide heavy dose are organized 200mg/kg, small dose group 100mg/kg and positive control drug puerarin injection group 150mg/kg, 10 every group.Tail vein injection administration 1 time.The administration volume is the 0.4ml/20g body weight.The blank group gives isometric solvent.30min begins the anoxia enduring experiment after administration.Mice is put into airtight wide mouthed bottle.Write down the time-to-live of mice when going into the bottle beginning to death.
The result shows that kakkalide can obviously prolong the time-to-live of mice anoxia enduring, with the blank group significant difference (P＜0.05) is arranged relatively, and the significantly ability of enhancing body anoxia enduring of kakkalide is described.The result sees table 1 for details.
Table 1 kakkalide is to the influence (x ± s n=10) of mice resisting oxygen lack
The group dosage time-to-live
(mg/kg) (min)
Blank group-11.23 ± 1.68
Kakkalide 200 15.78 ± 2.42
*
100 14.16±2.29
**
Puerarin injection 150 15.34 ± 2.55
*
Annotate: compare with the blank group,
*P＜0.05,
*P＜0.01
Two, kakkalide is to the protective effect of rat acute imperfection cerebral ischemia
With 50 Wistar rats (average weight 223.46 ± 16.72g), male and female half and half.Be divided into 5 groups at random, i.e. sham operated rats, cerebral ischemic model group, the heavy dose of group of kakkalide 100mg/kg, small dose group 50.0mg/kg, positive control drug puerarin injection group 80.0mg/kg.Every group 10.Intraperitoneal injection.Every day 1 time, successive administration 5 days.The administration volume is 1.0ml/200g, and sham operated rats and cerebral ischemic model group all give isometric solvent.30min begins experiment after the last administration.Rat is under 25% urethane (1g/kg) intraperitoneal injection of anesthesia, and the cervical region median incision separates bilateral carotid, and dual ligation (sham operated rats is only worn two-wire but not ligation) causes acute imperfection cerebral ischemia.After the ligation every group of 3h get 10 fast broken end get brain, the weighing botle of packing into claims cutaneous horn heavy, calculates cerebral index [cerebral index=cutaneous horn weight/body weight * 100%], places 110 ℃ of oven for baking 72 hours to constant weight then, claims brain stem heavy, the calculating brain water content.
The result shows the cerebral index of cerebral ischemic model group and brain water content apparently higher than sham operated rats (P＜0.05), illustrates that cerebral ischemic model sets up successfully.The large and small dosage group of kakkalide all obviously reduces the cerebral index and the brain water content of acute imperfection rats with cerebral ischemia, shows that kakkalide can obviously alleviate the caused cerebral edema of rat acute imperfection cerebral ischemia.The result sees table 2 for details.
Table 2. kakkalide to the influence of acute imperfection rats with cerebral ischemia cerebral index and brain water content (X ± s, n=10)
Dosage cerebral index brain water content
Group
(mg/kg) (％) (％)
Sham operated rats-0.498 ± 0.042
*78.21 ± 0.79
*
Cerebral ischemic model group-0.551 ± 0.046 80.05 ± 1.02
Kakkalide 100.0 0.504 ± 0.037
*78.83 ± 0.66
*
50.0 0.512±0.031
* 79.11±0.72
*
Puerarin injection 80.0 0.502 ± 0.049
*78.74 ± 0.84
*
Annotate: compare with the cerebral ischemic model group,
*P＜0.05,
*P＜0.01
Three, kakkalide is to the influence of anesthetized dog acute myocardial ischemia
20 of normal health dogs, body weight 11～15.5kg, male and female have concurrently, are divided into 4 groups at random, i.e. heavy dose of 50.0mg/kg, kakkalide small dose group 12.5mg/kg, positive control drug puerarin injection group 40.0mg/kg and the myocardial infarction and ischemia model group organized of kakkalide.Animal via 2.5% pentobarbital sodium (25mg/kg) intravenous anesthesia separates trachea and intubate, meets electric respirator pedestrian worker fully and breathes.The dog right arm reclining, breast is opened in the 4th intercostal space in the left side, makees the pericardium bed, separates nearly 1/2 place of left anterior descending coronary artery, and lead-in wire is equipped with ligation and uses.Epicardial lead is sewn on the visceral pericardium, leads the physiological signal acquisition analysis system record epicardial electrogram that links to each other more through band switch and BioPAC.The slow constant speed intravenous drip of postoperative normal saline is to replenish body fluid.30min record epicardial electrogram behind the ligation coronary artery, (∑-ST) and the displacement of ST section surpass leading of 2mv and count (N-ST) as being worth before the medicine to calculate the total value of 30 ST sections displacements of leading.Intravenous administration.The administration volume is 1.0ml/kg.The myocardial infarction and ischemia model group gives isopyknic solvent.Write down the epicardial electrogram that administration begins back 15min, 30min, 60min, 90min, 120min and 180min respectively, calculate ∑-ST, N-ST and rate of change thereof.3h after the administration injects burnt black ink 1.0ml/kg in the room left through the left auricle root, and 20-30 has annotated in second, takes off heart rapidly, removes fat, atrium and right ventricle's flesh, and freezing 30-40min under-20 ℃ weighs.Parallel coronary sulcus is cut into left ventricle 5 of uniform thickness under coronary artery ligation point, weigh respectively, measure burnt black ink dyeing district, every myocardium two sides (non-ischemic region) and district's (ischemic region) area that is unstained with planimeter, calculate the percentage rate that ischemic region accounts for left compartment muscle weight.Then 5 cardiac muscles are placed 37 ℃ of N-BT dye liquors, jolting dyeing 15min takes out, as above measure infarct (light red) and non-infarct (kermesinus) area, calculate infarct and account for the percentage rate of left compartment muscle weight, and calculate the percentage rate that infarct accounts for ischemic region cardiac muscle weight.
The result shows, the large and small dosage group of kakkalide respectively at administration after 30min～60min and 60min obviously alleviate anesthetized dog acute myocardial ischemia degree (∑-ST), though some not statistically significant At All Other Times, its drug action still may persist to 180min after the administration.The heavy dose of group of kakkalide 180min obviously dwindles anesthetized dog acute myocardial ischemia scope (N-ST) (P＜0.05), though small dose group does not have obviously influence, the trend of dwindling is arranged.The myocardial infarction area that shows with N-BT dyeing is consistent with the result that epicardial electrogram is measured.The large and small dosage group of kakkalide all has the damaging effect that obviously alleviates myocardial ischemia, and anesthetized dog acute myocardial infarction area is obviously dwindled, and with the myocardial infarction and ischemia model group notable difference (P＜0.05) is arranged more all respectively.The result sees table 3,4,5 for details.
Table 3. kakkalide is to dog acute myocardial ischemia degree (influence of ∑-ST) (n=5, X ± SD)
| Group | Dosage (g/kg) | Before the medicine | 15min behind the medicine | 30min behind the medicine | 60min behind the medicine | 90min behind the medicine | 120min behind the medicine | 180min behind the medicine | ||||||
| Current potential (mv) | Current potential (mv) | Rate of change (%) | Current potential (mv) | Rate of change (%) | Current potential (mv) | Rate of change (%) | Current potential (mv) | Rate of change (%) | Current potential (mv) | Rate of change (%) | Current potential (mv) | Rate of change (%) | ||
| The ischemia model group | - | 192.50± 105.86 | 189.10 ±83.08 | 3.89± 29.99 | 190.70± 82.50 | 6.44± 24.04 | 207.20± 90.00 | 15.71± 28.83 | 209.20± 117.47 | 23.03± 81.92 | 202.40± 106.65 | 28.47± 89.39 | 215.40± 108.44 | 42.77± 100.62 |
| Kakkalide | 50.0 | 173.40± 44.10 | 134.06 ± 60.40 | -23.12± 22.98 | 134.00± 50.79 | -23.92 ±13.68 * | 124.50± 53.10 | -30.21± 15.17 * | 108.80± 38.53 | -38.09± 9.27 | 89.95± 36.42 | -47.74± 12.26 | 83.40± 36.91 | -53.69± 10.36 |
| 12.5 | 219.10± 62.58 | 203.30 63.86 | -5.96± 21.79 | 176.26± 42.04 | -17.73 ±12.97 | 176.16± 41.70 | -17.66± 13.83 * | 158.00± 44.43 | -26.28± 17.39 | 132.60± 54.67 | -37.89± 18.42 | 127.40± 42.00 | -41.56± 11.34 | |
| Puerarin | 40.0 | 202.60± 134.22 | 187.80 ± 126.28 | -4.94± 22.94 | 160.30± 107.67 | -18.15 ±20.00 | 140.52± 84.48 | -27.32± 13.29 * | 117.36± 57.47 | -36.82± 13.66 | 98.70± 36.94 | -44.77± 14.66 * | 90.40± 39.10 | -49.68± 16.34 |
Annotate: compare with the ischemia model group
*P＜0.05,
*P＜0.01
Table 4 kakkalide is to the influence of dog acute myocardial ischemia scope (N-ST) (n=5, X ± SD)
| Group | Dosage (g/kg) | Before the medicine | 15min behind the medicine | 30min behind the medicine | 60min behind the medicine | 90min behind the medicine | 120min behind the medicine | 180min behind the medicine | ||||||
| Number (individual) leads | Number (individual) leads | Rate of change (%) | Number (individual) leads | Rate of change (%) | Number (individual) leads | Rate of change (%) | Number (individual) leads | Rate of change (%) | Number (individual) leads | Rate of change (%) | Number (individual) leads | Rate of change (%) | ||
| The ischemia model group | - | 28.80± 1.64 | 27.40± 3.44 | -5.11± 7.70 | 28.20± 2.17 | -2.15± 3.28 | 28.00± 2.35 | -2.89± 3.08 | 26.80± 4.66 | -7.33± 12.59 | 28.60± 1.67 | -0.59± 5.27 | 28.40± 1.82 | -1.41± 1.93 |
| Kakkalide | 50.0 | 25.60± 4.72 | 25.40± 4.16 | 0.26± 13.27 | 24.40± 3.85 | -3.95± 9.24 | 23.60± 4.67 | -7.81± 7.29 | 23.60± 3.91 | -7.00± 10.48 | 23.00± 4.06 | -9.64± 9.89 | 21.60± 6.50 | -16.64± 14.56 * |
| 12.5 | 28.20± 2.49 | 27.00± 3.74 | -4.52± 6.54 | 25.00± 3.74 | -11.40± 9.56 | 24.40± 4.72 | -13.71± 12.52 | 24.40± 4.16 | -13.78± 9.52 | 24.00± 3.94 | -14.54± 14.22 | 24.40± 4.04 | -13.38± 12.47 | |
| Puerarin injection | 40.0 | 24.60± 4.77 | 25.80± 2.95 | 6.72± 13.10 | 24.60± 3.91 | 1.16± 10.84 | 21.80± 6.26 | -10.60± 21.48 | 22.60± 5.73 | -6.98± 20.77 | 20.60± 5.41 | -16.35± 11.46 * | 20.80± 5.26 | -15.48± 11.40 * |
Annotate: compare with the ischemia model group
*P＜0.05,
*P＜0.01
Table 5. kakkalide is to the influence of dog acute myocardial ischemia area and infarct size (n=5, X ± SD)
Infarct weight/ischemic region
The heavy infarct weight/left ventricle of dosage ischemic region weight/left ventricle is heavy
Group is heavy
(g/kg) (％) (％)
(％)
Ischemia model group-14.78 ± 4.72 11.06 ± 2.73 76.96 ± 10.80
Kakkalide 50.0 12.88 ± 3.35 6.31 ± 1.78
*50.36 ± 14.57
*
12.5 12.65±6.82 6.06±2.27
* 51.77±16.14
*
Puerarin injection 40.0 11.00 ± 3.25 5.72 ± 0.77
*54.59 ± 11.36
*
Annotate: compare with the ischemia model group
*P＜0.05
Four, kakkalide is to the therapeutical effect of castrated rats osteoporosis model
50 male rats (body weight 170-200g) are divided into 5 groups at random, are respectively blank group, osteoporosis model group, the heavy dose of group of kakkalide 100mg/kg, small dose group 50.0mg/kg, positive control drug Gaierqi D (vitamin D3 and calcium carbonate) group 500mg/kg.Every group 10.Except that the blank group, all the other five groups all capable bilateral testes enucleation are made the castrated rats osteoporosis model.Postoperative beginning in 3 days intraperitoneal injection, once a day, continuous 60 days.Next day, jugular vein was got blood examination survey serum calcium (s-Ca), serum paraoxonase (s-P), alkali phosphatase (ALP) after drug withdrawal, got the bilateral femur and carried out calcium content of bone mensuration.
The result shows, osteoporosis model treated animal femur calcium content of bone and the apparent in view reduction of normal control group, and successive administration 60 days can obviously increase the deposition of femur bone calcium under 50～100mg/kg dosage, make bone calcium level obviously raise (P＜0.01).But kakkalide does not have obvious influence (table 6,7) to blood calcium, serium inorganic phosphorus, the alkali phosphatase of castrated rats.
Table 6. kakkalide causes influence (n=10, the X ± SD) of osteoporosis model serological index to castrated rats
Dosage serum calcium serum paraoxonase alkali phosphatase
Group
(mg/kg) (mmol/L) (mmol/L) (IU/L)
The normal control group--2.24 ± 0.13 2.89 ± 1.21 128.70 ± 16.74
Model control group--2.33 ± 0.25 2.41 ± 0.32 117.20 ± 33.17
Gaierqi D (vitamin D3 and calcium carbonate) 500 2.32 ± 0.30 2.56 ± 0.27 129.50 ± 18.33
Kakkalide 100 2.21 ± 0.24 2.33 ± 0.29 134.70 ± 47.28
50.0 2.42±0.23 2.35±0.32 122.73±28.35
Annotate: compare P＞0.05 with model control group
Table 7. kakkalide is to the sedimentary influence of castrated rats bone calcium (n=10, X ± SD)
The dosage calcium content of bone
Group
(mg/kg) (mg/g)
The normal control group--113.82 ± 24.93
*
Model control group--84.62 ± 16.53
Gaierqi D (vitamin D3 and calcium carbonate) 500 99.86 ± 13.27
*
Kakkalide 100 118.69 ± 20.38
*
50.0 106.30±19.43
*
Annotate: compare with model control group,
*P＜0.01
Five, the kakkalide oral administration is to the influence of mice anoxia enduring
50 of Kunming mouses, male and female half and half are divided into 4 groups at random, and promptly blank group, kakkalide heavy dose are organized 400mg/kg, small dose group 200mg/kg and positive control drug puerarin injection group 150mg/kg, 10 every group.Gastric infusion.Successive administration 5 days, every day 1 time.The administration volume is the 0.4ml/20g body weight.The blank group gives isometric solvent.1h begins the anoxia enduring experiment after the last administration.Mice is put into airtight wide mouthed bottle.Write down the time-to-live of mice when going into the bottle beginning to death.
The result shows that kakkalide can obviously prolong the time-to-live of mice anoxia enduring, with the blank group significant difference (P＜0.05) is arranged relatively, and the significantly ability of enhancing body anoxia enduring of kakkalide is described.The result sees table 8 for details.
Table 8 kakkalide is to the influence (x ± s n=10) of mice resisting oxygen lack
The group dosage time-to-live
(mg/kg) (min)
Blank group-16.02 ± 3.37
Kakkalide 400 22.41 ± 5.41
*
200 20.65±5.72
*
Puerarin injection 150 21.96 ± 4.38
*
Annotate: compare with the blank group,
*P＜0.05,
*P＜0.01
Six, the kakkalide oral administration causes the influence of Acute Myocardial Ischemia in Rats to pituitrin
With 40 of Wistar rats, body weight 223 ± 17g, male and female half and half.Be divided into 4 groups at random, i.e. the heavy dose of group of kakkalide 200mg/kg, small dose group 100.0mg/kg, positive control drug puerarin injection group 80.0mg/kg and blank group.Every group 10.Gastric infusion.The administration volume is 2.0ml/200g.Successive administration 5 days, every day 1 time.The blank group gives isopyknic solvent.Behind last administration 1h, begin to detect electrocardiogram.Rat is with 2.5% pentobarbital sodium intraperitoneal anesthesia, and it is fixing to lie on the back.It is subcutaneous to thrust extremity with needle electrode, and record II lead electrocardiogram is as basic electrocardiogram contrast.Tail vein injection pituitrin 0.8U/kg then injects in 10s and finishes.The electrocardiogram of 5s, 10s, 15s, 30s, 1min, 2min, 3min behind the immediate record injection of pituitrin is observed the variation of T ripple, ST section and heart rate.Person of following index occurring with electrocardiogram is positive myocardial ischemia: more than the J point rising 1.5mv, and T ripple low flat (reducing former T wave height more than 50%), two-way, inversion, ST section level moves down 0.5mv, arrhythmia.
The result shows that the large and small dosage group of kakkalide all can obviously reduce by the acute myocardial ischemia positive rate due to the pituitrin, with the blank group notable difference (P＜0.05) table 9 is arranged relatively.
Table 9 kakkalide causes the antagonism of Acute Myocardial Ischemia in Rats to pituitrin
| Group | Dosage (mg/kg) | Number of animals (only) | Myocardial ischemia (%) | The P value | |
| Negative rate | Positive rate | ||||
| Blank group kakkalide puerarin injection | - 200.0 100.0 80.0 | 10 10 10 10 | 0 70 50 60 | 100 30 50 40 | - ＜0.01 ＜0.05 ＜0.01 |
Seven, the kakkalide oral administration is not exclusively given birth to the protective effect of cerebral ischemia to rat acute
With 50 Wistar rats (average weight 202.32 ± 21.40g), male and female half and half.Be divided into 5 groups at random, i.e. sham operated rats, cerebral ischemic model group, the heavy dose of group of kakkalide 200mg/kg, small dose group 100mg/kg, positive control drug puerarin injection group 80.0mg/kg.Every group 10.Gastric infusion.Every day 1 time, successive administration 5 days.The administration volume is 1.0ml/200g, and sham operated rats and cerebral ischemic model group all give isometric solvent.1h begins experiment after the last administration.Rat is under 25% urethane (1g/kg) intraperitoneal injection of anesthesia, and the cervical region median incision separates bilateral carotid, and dual ligation (sham operated rats is only worn two-wire but not ligation) causes acute imperfection cerebral ischemia.After the ligation every group of 3h get 10 fast broken end get brain, the weighing botle of packing into claims cutaneous horn heavy, calculates cerebral index [cerebral index=cutaneous horn weight/body weight * 100%], places 110 ℃ of oven for baking 72 hours to constant weight then, claims brain stem heavy, the calculating brain water content.
The result shows the cerebral index of cerebral ischemic model group and brain water content apparently higher than sham operated rats (P＜0.05), illustrates that cerebral ischemic model sets up successfully.The large and small dosage group of kakkalide all obviously reduces the cerebral index and the brain water content of acute incomplete living rats with cerebral ischemia, shows that kakkalide can obviously alleviate the caused cerebral edema of rat acute imperfection cerebral ischemia.The result sees table 10 for details.
Table 10. kakkalide oral administration is to acute imperfection rats with cerebral ischemia cerebral index
With the influence of brain water content (X ± s, n=10)
Dosage cerebral index brain water content
Group
(mg/kg) (％) (％)
Sham operated rats-0.433 ± 0.042
*77.51 ± 0.64
*
Cerebral ischemic model group-0.517 ± 0.051 79.69 ± 0.99
Kakkalide 100.0 0.455 ± 0.039
*78.27 ± 0.71
*
50.0 0.479±0.033 78.76±0.83
*
Puerarin injection 80.0 0.463 ± 0.041
*78.34 ± 0.91
*
Annotate: compare with the cerebral ischemic model group,
*P＜0.05,
*P＜0.01
Eight, the kakkalide oral administration is to the therapeutical effect of castrated rats osteoporosis model
(average weight 197.84 ± 14.62g) is divided into 5 groups at random, is respectively blank group, osteoporosis model group, the heavy dose of group of kakkalide 200mg/kg, small dose group 100mg/kg, positive control drug Gaierqi D (vitamin D3 and calcium carbonate) group 500mg/kg with 50 male rats.Every group 10.Except that the blank group, all the other five groups all capable bilateral testes enucleation are made the castrated rats osteoporosis model.Postoperative beginning in 3 days intraperitoneal injection, once a day, continuous 60 days.Next day, jugular vein was got blood examination survey serum calcium (s-Ca), serum paraoxonase (s-P), alkali phosphatase (ALP) after drug withdrawal, got the bilateral femur and carried out calcium content of bone mensuration.
The result shows, osteoporosis model treated animal femur calcium content of bone and the apparent in view reduction of normal control group, successive administration 60 days, 200mg/kg can obviously increase the deposition of femur bone calcium, the bone calcium level is obviously raise (P＜0.01), and 100mg/kg has increase trend.The result sees table 11 for details.
Table 11 kakkalide oral administration to the sedimentary influence of castrated rats bone calcium (X ± s, n=10)
The dosage calcium content of bone
Group
(mg/kg) (mg/g)
Normal control group-115.73 ± 19.58
*
Model control group-86.35 ± 13.04
Gaierqi D (vitamin D3 and calcium carbonate) 500 100.61 ± 17.09
Kakkalide 200 108.21 ± 18.33
*
100 98.11±15.03
Annotate: compare with model control group,
*P＜0.01
The kakkalide mtd test
Select 20 of healthy Kunming mouses, body weight 18～20g, male and female half and half.Tail vein injection gives 3% kakkalide.The administration volume is the 0.5ml/20g body weight.Every 2h administration 1 time, totally 4 times.At once do not see all after the administration that overt toxicity reaction, no dead mouse appear in animal.Continue to observe the mice well-grown 14 days.Comprehensive above-mentioned experimental result shows:
1, kakkalide can obviously prolong the time-to-live of mice anoxia enduring, with the blank group significant difference (P＜0.05) is arranged relatively, and the significantly ability of enhancing body anoxia enduring of kakkalide is described.
2, the large and small dosage group of kakkalide all obviously reduces the cerebral index and the brain water content of acute imperfection rats with cerebral ischemia, shows that kakkalide can obviously alleviate the caused cerebral edema of rat acute imperfection cerebral ischemia.
3, the large and small dosage group of kakkalide all has the damaging effect that obviously alleviates myocardial ischemia, and anesthetized dog acute myocardial infarction area is obviously dwindled, and with the myocardial infarction and ischemia model group notable difference (P＜0.05) is arranged more all respectively.
4, kakkalide is to castrated rats osteoporosis model treated animal femur calcium content of bone and the apparent in view reduction of normal control group, successive administration 60 days, the obvious deposition of share increase bone bone calcium under 50-100mg/kg dosage makes bone calcium level obviously raise (P＜0.01).But kakkalide does not have obvious influence to blood calcium, serium inorganic phosphorus, the alkali phosphatase of castrated rats.
By the above pharmacologically active that experimental results show that kakkalide, thereby confirm that kakkalide can be used for the preparation treatment ischemic heart, cerebrovascular pharmaceutical composition, in described pharmaceutical composition, contain kakkalide, and acceptable carrier pharmaceutically, experiment has proved that also kakkalide also can be used to prepare the pharmaceutical composition for the treatment of osteoporosis.
Kakkalide can only be made the oral medicine preparation at present, and can not make injection drug because water solublity hangs down when medicinal, also has influence on drug utilization degree and remarkable time.Particularly, more be not easy to select clinically use as the medicine of the treatment heart, cerebrovascular.So an important feature of the present invention is to be added with solubilizing agent in kakkalide pharmaceutical composition of the present invention, thereby has improved the water solublity of kakkalide.Table 12 has been enumerated the data of partial solvent to the kakkalide solubilization.
The dissolubility of table 12 kakkalide in partial solvent
| Solvent strength | 1％ | 3％ | 5％ | 10％ | 20％ | 50％ | 100％ |
| Water | Insoluble | ||||||
| Beta-schardinger dextrin- | 0.05％ | 0.1％ | 0.2％ | 0.8％ | 1.2％ | 2％ | |
| HP- | 0.2％ | 0.5％ | 1％ | 1.5％ | 3％ | 7％ | |
| Hydroxyethyl- | 0.15％ | 0.4％ | 0.8％ | 1.2％ | 2％ | 4％ |
Select by experiment, contained solubilizing agent in the said kakkalide pharmaceutical composition of the present invention, it is selected from HP-, propylene glycol, ethanol, Tween 80, glucose, beta-schardinger dextrin-, hydroxyethyl-, Macrogol 600, the Polyethylene Glycol 800 one or more.Wherein preferably beta-schardinger dextrin-, hydroxyethyl-and HP-.The content of kakkalide pharmaceutical composition solubilizing agent is 0-50wt% by weight percentage, and in view of solubilizing agent reduces less than the 5wt% dissolubility, it is poor to be higher than 50wt% viscosity high fluidity, is unfavorable for making injection, so its preferred content is 5-20wt%.When being solubilizing agent with the HP-, its preferred content is 5-15wt%.
By above improvement, like this kakkalide pharmaceutical composition that constitutes has improved the water solublity and the bioavailability of kakkalide.Both can kakkalide be prepared into the various oral formulations for the treatment of the heart, cerebrovascular and treatment osteoporosis with conventional method, main is to make injection, provides convenience for selecting clinically to use.
The invention will be further described with experimental example more below:
The preparation of embodiment 1. kakkalide
In the present embodiment, the dried Flos Pueraria omeiensis of 10kg is pulverized, with 90% alcoholic solution reflux, extract, 2 times, each 3 hours, filter, collect filtrate, reclaim ethanol and do not distinguish the flavor of to there being alcohol, add 6 times of water gagings of solution, placement is spent the night, and gets supernatant.Cross macroporous resin, use 60% ethanol elution, eluent reclaims, and places and separates out crystallization, filter, drying, the reuse acetone recrystallization, filter kakkalide.
Example 2.
With 1000 of preparation kakkalide injection is that used raw material of example and ratio of adjuvant are as follows:
Kakkalide 100g
HP-500g
Sodium calcium edetate 1g
Sodium sulfite 10g
Water for injection adds to 10L
Adopt the preparation technology of conventional injection to make, every bottle heavy 10 order 10ml, every bottle contains kakkalide 100mg.Usage: be grown up once-a-day, each 6 bottles of intravenous injections, the child takes the circumstances into consideration decrement.
Example 3.
With preparation kakkalide injection 100ml, 1000 bottles is that used raw material of example and ratio of adjuvant are as follows:
Kakkalide 1000g
Hydroxypropyl beta cyclodextrin 3000g
Sodium calcium edetate 1g
Sodium sulfite 10g
Water for injection adds to 10L
Adopt the preparation technology of conventional injection to make, every bottle of 100ml, every bottle contains kakkalide 1mg.Usage: be grown up 1 time on the one, each 1 bottle of intravenous injection, the child takes the circumstances into consideration decrement.
Claims (9)
1. the purposes of kakkalide in the preparation treatment heart, cerebrovascular drug regimen medicine, wherein said pharmaceutical composition contains kakkalide, and acceptable carrier pharmaceutically.
2. the application of kakkalide in preparation treatment medicine for treating osteoporosis.
3. require the purposes of 1 or 2 kakkalide in pharmaceutical compositions according to claim, include pharmaceutically acceptable carrier in the said kakkalide pharmaceutical composition, it is characterized in that containing in the compositions solubilizing agent.
4. according to the described kakkalide pharmaceutical composition of claim 3, it is characterized in that said solubilizing agent content is 0～50wt% by weight percentage.
5. according to the described kakkalide pharmaceutical composition of claim 3, it is characterized in that said solubilizing agent content is 5～20wt%. by weight percentage
6. according to the described kakkalide pharmaceutical composition of claim 3, it is characterized in that said solubilizing agent is selected from one or more in hydroxypropyl beta cyclodextrin, propylene glycol, ethanol, Tween 80, glucose, beta-schardinger dextrin-, hydroxyethyl-, Macrogol 600, the Polyethylene Glycol 800.
7, according to the described kakkalide pharmaceutical composition of claim 3, it is characterized in that said solubilizing agent is a HP-, its content is 5～15wt%.
8. according to the purposes of the described kakkalide of claim 1, it is characterized in that the pharmaceutical composition of said kakkalide, be prepared into the injection of treatment cardiovascular and cerebrovascular vessel medicine.
9. according to the purposes of the described kakkalide of claim 2, it is characterized in that the pharmaceutical composition of said kakkalide, be prepared into the injection of treatment medicine for treating osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100439683A CN100471500C (en) | 2005-07-04 | 2005-07-04 | Medicinal composition contg. glucoside of pueravia flower and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100439683A CN100471500C (en) | 2005-07-04 | 2005-07-04 | Medicinal composition contg. glucoside of pueravia flower and its application |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101771345A Division CN101444523B (en) | 2005-07-04 | 2005-07-04 | Application of pueraria flower glucoside in preparation of medical compound for remedying osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1723988A true CN1723988A (en) | 2006-01-25 |
| CN100471500C CN100471500C (en) | 2009-03-25 |
Family
ID=35923705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100439683A Expired - Fee Related CN100471500C (en) | 2005-07-04 | 2005-07-04 | Medicinal composition contg. glucoside of pueravia flower and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100471500C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239092B (en) * | 2008-03-14 | 2010-10-20 | 山东省医学科学院药物研究所 | Kudzuvine flower isoflavonoid extraction, its extracting method, medicinal composition and its use in pharmaceutical |
| CN101357933B (en) * | 2008-09-09 | 2011-08-31 | 中国人民解放军第二军医大学 | Method for separating isoflavones monomeric compound in Belamcanda chinensis by high speed countercurrent chromatography |
| CN112353837A (en) * | 2020-12-01 | 2021-02-12 | 益家元品实业（厦门）有限公司 | Flos puerariae lobatae extract and its use |
| CN112451559A (en) * | 2020-09-30 | 2021-03-09 | 益家元品实业（厦门）有限公司 | Use of flos Puerariae Lobatae extract in preventing and treating oxidative damage |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1594307A (en) * | 2004-06-25 | 2005-03-16 | 陕西师范大学 | Extraction separation for Nepal irid isoflavone from kudzu, process for preparing sulfonated compounds thereof , and their pharmaceutical uses |
-
2005
- 2005-07-04 CN CNB2005100439683A patent/CN100471500C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101239092B (en) * | 2008-03-14 | 2010-10-20 | 山东省医学科学院药物研究所 | Kudzuvine flower isoflavonoid extraction, its extracting method, medicinal composition and its use in pharmaceutical |
| CN101357933B (en) * | 2008-09-09 | 2011-08-31 | 中国人民解放军第二军医大学 | Method for separating isoflavones monomeric compound in Belamcanda chinensis by high speed countercurrent chromatography |
| CN112451559A (en) * | 2020-09-30 | 2021-03-09 | 益家元品实业（厦门）有限公司 | Use of flos Puerariae Lobatae extract in preventing and treating oxidative damage |
| CN112353837A (en) * | 2020-12-01 | 2021-02-12 | 益家元品实业（厦门）有限公司 | Flos puerariae lobatae extract and its use |
| CN112353837B (en) * | 2020-12-01 | 2022-06-07 | 益家元品实业（厦门）有限公司 | Flos puerariae extract and its use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100471500C (en) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1299694C (en) | Flavone composition for sobering and liver protection and its use | |
| CN1304039C (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN101033245A (en) | Preparation method and application of pedunculoside | |
| CN1723988A (en) | The pharmaceutical composition of kakkalide and application thereof | |
| CN1771944A (en) | Application of high-solubility berberine in preparing medicine | |
| CN1857654A (en) | Trachaitis treating preparation and its preparing process | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN1712056A (en) | Medicinal composition, preparation and quality control thereof | |
| CN1568960A (en) | High purity chlorogenic acid prescription | |
| CN1608662A (en) | Medicine with antiphlogistic, analgetic, microbiostatic and diuretic effects | |
| CN1772026A (en) | Whorlleaf stonecrop herb extract and its extraction process and prepn | |
| CN101028518A (en) | Medicinal composition containing silver ester medicine and ibobulodine | |
| CN1883585A (en) | Pharmaceutical composition for treating atherosclerosis and method for preparing same | |
| CN1899560A (en) | Compound preparation for treating summer wet type cold and its preparing method | |
| CN101444523B (en) | Application of pueraria flower glucoside in preparation of medical compound for remedying osteoporosis | |
| CN100337665C (en) | Oral medicine for treating diabetes | |
| CN1494902A (en) | Application of high-solubility berberine in preparation of medicine. | |
| CN1203886C (en) | Medicine for treating cardiovascular diseases and its preparing method | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN101077873A (en) | Novel NEO-clerodane type diterpene compound and application thereof | |
| CN1899397A (en) | Heart activating oral disintergration tablet and its preparing method | |
| CN1511535A (en) | Use of spirosterol type steroid saponin in preparing medicine for treating cardio-cerebral vascular disease | |
| CN1406585A (en) | Medicinal composition for viral myocarditis | |
| CN1813775A (en) | Use of icariin for preparing medicine for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING RONGNENG TECHNOLOGY & TRADE CO., LTD. Free format text: FORMER OWNER: PHARMACEUTICAL RESEARCH INST. OF SHANDONG PROV. MEDICAL SCIENCE ACADEMY Effective date: 20080328 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080328 Address after: The eight district of Beijing City, right outside the Shenyang No. 24 in B post encoding: 100069 Applicant after: Beijing able Technology & Trade Co., Ltd. Address before: Postcode 89, No. ten, Lixia District, Ji'nan City, Shandong Province, China: 250062 Applicant before: Medicine Research Inst., Shandong Prov. Medical Science Academy |
|
| ASS | Succession or assignment of patent right |
Owner name: PHARMACEUTICAL RESEARCH INST. OF SHANDONG PROV. M Free format text: FORMER OWNER: BEIJING RONGNENG TECHNOLOGY + TRADE CO., LTD. Effective date: 20081107 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20081107 Address after: Postal code 89, No. ten, 250062, Shandong, Ji'nan Applicant after: Medicine Research Inst., Shandong Prov. Medical Science Academy Address before: The eight district of Beijing City, right outside the Shenyang No. 24 in B post encoding: 100069 Applicant before: Beijing able Technology & Trade Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090325 Termination date: 20100704 |